62643-19-0

Usage

Uses

Used in Biomedical Applications:
4-Oxepanone is used as a monomer for the production of biodegradable polyesters such as poly(p-dioxanone) (PPDO). These polyesters are utilized in the medical field for applications like sutures, implants, and drug delivery systems, taking advantage of their biocompatibility and biodegradability.
Used in Chemical Synthesis:
4-Oxepanone is used as a solvent in organic chemical reactions, facilitating various processes in the chemical industry. Its properties make it a valuable component in the synthesis of different organic compounds.
Used in Organic Synthesis:
4-Oxepanone is also employed as a reagent in organic synthesis, contributing to the creation of a wide range of organic compounds for diverse applications across the chemical sector.

Upstream product

• 186581-53-3 diazomethane 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 67-56-1 methanol 
• 60-29-7 diethyl ether 
• 592-90-5 oxepane 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 615-53-2 ethyl N-methyl-N-nitrosocarbamate 
• 2081-44-9 Tetrahydro-pyran-4-ol 
• 119124-52-6 Se-Phenyl 4-Oxaselenohept-6-enoate 
• 22577-15-7 3-(allyloxy)propionic acid 

Downstream Products

• 106377-75-7 oxepan-4-one-(4-phenyl semicarbazone) 
• 100120-96-5 oxepan-4-one-(2,4-dinitro-phenylhydrazone) 
• 894400-02-3 4-(4-iodophenyl)oxepan-4-ol 
• 693247-46-0 C₂₄H₃₂F₆N₂O₂ 
• 894399-98-5 4-(4-iodophenyl)-4-methoxyoxepane 
• 1425971-80-7 4-{4-[(1-cyclobutylpiperidin-4-ylidene)methyl]phenyl}oxepan-4-ol 
• 1425971-81-8 4-{4-[(1-cyclobutylpiperidin-4-ylidene)methyl]phenyl}oxepan-4-ol 
• 130722-83-7 4-methoxy-4-[3-(naphth-2-ylmethoxy)phenyl]oxepane 

Relevant academic research and scientific papers

Aminopyridyloxypyrazole derivative and preparation method and application thereof

The invention relates to an aminopyridyloxypyrazole derivative and a preparation method and application thereof. The structure of the aminopyridyloxypyrazole derivative is shown as a formula (I). The invention provides a brand-new aminopyridyloxypyrazole derivative which has obvious effects of inhibiting TGF [beta] R1 (ALK5) kinase activity and treating cancer or fibrosis related diseases, and the preparation method of the derivative is simple and easy to operate.

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

TDO2 INHIBITORS

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.

N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.

PYRAZOLOQUINOLINE DERIVATIVES

A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.

New methylene homologation method for cyclic ketones

Teaching new tricks to an old dog: By intercepting adducts between ketones and lithium trimethylsilyldiazomethane, a new Tiffeneau-Demjanov type methylene homologation could be realized in a single-step operation. Among proton sources and Lewis acids, silica gel was found to be the most effective reagent for the protonation of intermediates and their subsequent ring expansion (see scheme). Copyright

PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R2, R3, R4, R5, R6, R7, R9, X1, X2, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

HETEROTRICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to azatricyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 a